


CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date below:

6-30-05
Date


David L. Parker

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Arap, et al.

U.S. Appl. No.: 10/530,168

PCT Appl. No. PCT/US02/34987

Intl. Filing Date: 10/30/02

For: COMPOSITIONS AND METHODS FOR
USE OF TARGETING PEPTIDES FOR
DIAGNOSIS AND THERAPY OF
HUMAN CANCER

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:857US

RENEWED PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION
FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY
UNDER 37 CFR 1.137(B) FILED 04 APRIL 2005

Mail Stop PCT
Commissioner for Patents
Office of PCT Legal Administration
P. O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

On April 4, 2005, Applicants filed a Petition for Revival of an International Application for Patent Designating the United States Abandoned Unintentionally under 37 C.F.R. § 1.137(b) in the above-referenced international application (the "First Petition"). On June 20, 2005, the Office mailed a Decision dismissing the First Petition due to Applicants failure to pay the

national filing fees. Applicants complied with all other requirements for revival of the above-referenced international application, including a statement that the entire delay was unintentional, a statement that no terminal disclaimer was required since the international application was filed after June 8, 1995, and payment of the \$750.00 petition fee. For the convenience of the Office, Applicants submit herewith a copy of the First Petition is attached as Appendix A.

Pursuant to the statements of the Decision, Applicants submit this Renewed Petition for Revival of an International Application for Patent Designating the U.S. Abandoned Unintentionally Under 37 CFR 1.137(b) filed 04 April 2005 (the "Renewed Petition"). Together with this Renewed Petition, Applicants submit a proper reply in the form of a Transmittal Letter to the United States Designated/Elected Office Concerning a Submission Under 35 U.S.C. 371 and the required national filing fees.

Applicants believe that they have now met all the requirements for revival of the above-referenced international application, and such favorable action is respectfully requested.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:857US.

Respectfully submitted,



David L. Parker
Reg. No. 32,165
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.

600 Congress Avenue, Suite 2400

Austin, Texas 78701

(512) 474-5201

(512) 536-4598 (facsimile)

Date: June 30, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT
DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number
(Optional)
UTSC:857US

First Named Inventor: Wadih Arap

International (PCT) Application No.: PCT/US2002/34987

U.S. Application No.:
(if known)

Filed: October 30, 2002

Title: Compositions and Methods of Use of Targeting Peptides for Diagnosis and Therapy of Human Cancer

Attention: PCT Legal Staff
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

Small entity - fee \$ 750.00 (37 CFR 1.17(m)). Applicant claims small entity status.
See 37 CFR 1.27.

Other than small entity - fee \$ _____ (37 CFR 1.17(m))

2. Proper reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of
Transmittal to United States Designated/Elected Office Concerning a Filing (identify type of reply):
under 37 U.S.C. 371

has been filed previously on _____.

is enclosed herewith.

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

- Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.
- A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

April 4, 2005

Date

David L. Parker

32,165

Typed or Printed Name

Registration Number, if applicable

600 Congress Avenue, Suite 2400

512-536-3055

Address

Telephone Number

Austin, TX 78701

Address

Enclosures: Response Fee Payment Terminal Disclaimer Other (please identify):

return postcard

EXPRESS MAIL NO: EV 603378994 US
MAILING DATE: April 4, 2005